[A25-114] Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis) – Benefit assessment according to §35a Social Code Book V
Last updated 05.03.2026
Project no.:
A25-114
Commission:
Commission awarded on 04.09.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A25-114
| Project no. | Title | Status |
|---|---|---|
| G22-05 | Avacopan (severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphamide) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A26-07 | Avacopan (granulomatosis with polyangiitis or microscopic polyangiitis) – Addendum to Project A25-114 | Commission completed |
Federal Joint Committee (G-BA)
05-03-2026 A G-BA decision was published.
G-BA documents on this decision